| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bernard Le Foll, Zuzana Justinova, Gianlugi Tanda, Steven R Goldber. [Future medications for tobacco and cannabis dependence]. Bulletin de l'Academie nationale de medecine. vol 192. issue 1. 2008-10-16. PMID:18663981. |
cannabinoids, which are usually used in the form of marijuana, have become the most frequently used illicit drugs, but there is no pharmacological treatment for marijuana dependence. |
2008-10-16 |
2023-08-12 |
Not clear |
| Michelle L Holland, John D Allen, Jonathon C Arnol. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). European journal of pharmacology. vol 591. issue 1-3. 2008-10-15. PMID:18619955. |
indeed, the cannabinoids enhanced the intracellular accumulation of two abcc1 substrates, fluo3 and vincristine, in ovarian carcinoma cells over-expressing abcc1 (2008/mrp1) with a rank order of potency: cannabidiol>cannabinol>delta(9)-tetrahydrocannabinol. |
2008-10-15 |
2023-08-12 |
Not clear |
| Julie Desroches, Pierre Beaulie. [The cannabinoid system and pain: a new therapeutic avenue?]. Revue medicale suisse. vol 4. issue 162. 2008-10-03. PMID:18649597. |
nevertheless, cannabis and cannabinoids as analgesic agents have not been yet unequivocally established. |
2008-10-03 |
2023-08-12 |
Not clear |
| Francesca Comelli, Gabriella Giagnoni, Isabella Bettoni, Mariapia Colleoni, Barbara Cost. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytotherapy research : PTR. vol 22. issue 8. 2008-10-02. PMID:18618522. |
it was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non-cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain. |
2008-10-02 |
2023-08-12 |
rat |
| Kirsten R Müller-Vahl, Hinderk M Emric. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert review of neurotherapeutics. vol 8. issue 7. 2008-10-01. PMID:18590475. |
cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. |
2008-10-01 |
2023-08-12 |
Not clear |
| Barbara L F Kaplan, Alison E B Springs, Norbert E Kaminsk. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochemical pharmacology. vol 76. issue 6. 2008-09-29. PMID:18656454. |
cannabidiol (cbd) is a cannabinoid compound derived from cannabis sativa that does not possess high affinity for either the cb1 or cb2 cannabinoid receptors. |
2008-09-29 |
2023-08-12 |
mouse |
| M M Caffarel, G Moreno-Bueno, C Cerutti, J Palacios, M Guzman, F Mechta-Grigoriou, C Sanche. JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. vol 27. issue 37. 2008-09-24. PMID:18454173. |
it has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. |
2008-09-24 |
2023-08-12 |
human |
| F Van der Kooy, B Pomahacova, R Verpoort. Cannabis smoke condensate I: the effect of different preparation methods on tetrahydrocannabinol levels. Inhalation toxicology. vol 20. issue 9. 2008-09-04. PMID:18645719. |
cannabis sativa contains more than 400 known compounds, of which the terpene chemicals, called cannabinoids, are unique to this species. |
2008-09-04 |
2023-08-12 |
Not clear |
| Jürg Gertsc. Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system. Planta medica. vol 74. issue 6. 2008-08-21. PMID:18275004. |
since the discovery that endogenous lipid mediators show similar cannabimimetic effects as phytocannabinoids from cannabis sativa, our knowledge about the endocannabinoid system has rapidly expanded. |
2008-08-21 |
2023-08-12 |
human |
| Puspha Sinnayah, Erin E Jobst, Joseph A Rathner, Angela D Caldera-Siu, Luciana Tonelli-Lemos, Aaron J Eusterbrock, Pablo J Enriori, Emmanuel N Pothos, Kevin L Grove, Michael A Cowle. Feeding induced by cannabinoids is mediated independently of the melanocortin system. PloS one. vol 3. issue 5. 2008-08-19. PMID:18493584. |
cannabinoids, the active components of marijuana, stimulate appetite, and cannabinoid receptor-1 (cb1-r) antagonists suppress appetite and promote weight loss. |
2008-08-19 |
2023-08-12 |
Not clear |
| Martin Cohen, Nadia Solowij, Vaughan Car. Cannabis, cannabinoids and schizophrenia: integration of the evidence. The Australian and New Zealand journal of psychiatry. vol 42. issue 5. 2008-08-14. PMID:18473254. |
cannabis, cannabinoids and schizophrenia: integration of the evidence. |
2008-08-14 |
2023-08-12 |
Not clear |
| Martin Cohen, Nadia Solowij, Vaughan Car. Cannabis, cannabinoids and schizophrenia: integration of the evidence. The Australian and New Zealand journal of psychiatry. vol 42. issue 5. 2008-08-14. PMID:18473254. |
the aim is to assist clinicians to probe more deeply into the newly unfolding world of cannabinoid physiology and to critically evaluate the potential role of cannabis in the onset and persistence of cognitive impairments and psychosis in otherwise healthy users and in schizophrenia. |
2008-08-14 |
2023-08-12 |
Not clear |
| Patrick D Skosnik, Chad R Edwards, Brian F O'Donnell, Ashley Steffen, Joseph E Steinmetz, William P Hetric. Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 6. 2008-08-07. PMID:17637608. |
cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. |
2008-08-07 |
2023-08-12 |
mouse |
| Celia J A Morgan, H Valerie Curra. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. The British journal of psychiatry : the journal of mental science. vol 192. issue 4. 2008-08-07. PMID:18378995. |
cannabis contains various cannabinoids, two of which have almost opposing actions: delta9-tetrahydrocannabinol (delta9-thc) is psychotomimetic, whereas cannabidiol (cbd) has antipsychotic effects. |
2008-08-07 |
2023-08-12 |
Not clear |
| Celia J A Morgan, H Valerie Curra. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. The British journal of psychiatry : the journal of mental science. vol 192. issue 4. 2008-08-07. PMID:18378995. |
this provides evidence of the divergent properties of cannabinoids and has important implications for research into the link between cannabis use and psychosis. |
2008-08-07 |
2023-08-12 |
Not clear |
| Stephen I Deutsch, Richard B Rosse, Julie M Connor, Jessica A Burket, Mary E Murphy, Fiona J Fo. Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. CNS spectrums. vol 13. issue 5. 2008-08-07. PMID:18496477. |
a substantial percentage of patients with ms report subjective benefit from what is often illicit abuse of extracts of the cannabis sativa plant; the main cannabinoids include delta-9-tetrahydrocannabinol (delta9-thc) and cannabidiol. |
2008-08-07 |
2023-08-12 |
Not clear |
| Jürg Gertsch, Marco Leonti, Stefan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak, Andreas Zimme. Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 26. 2008-07-31. PMID:18574142. |
the psychoactive cannabinoids from cannabis sativa l. and the arachidonic acid-derived endocannabinoids are nonselective natural ligands for cannabinoid receptor type 1 (cb(1)) and cb(2) receptors. |
2008-07-31 |
2023-08-12 |
mouse |
| Jürg Gertsch, Marco Leonti, Stefan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak, Andreas Zimme. Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 26. 2008-07-31. PMID:18574142. |
these results identify (e)-bcp as a functional nonpsychoactive cb(2) receptor ligand in foodstuff and as a macrocyclic antiinflammatory cannabinoid in cannabis. |
2008-07-31 |
2023-08-12 |
mouse |
| Viviana Trezza, Vincenzo Cuomo, Louk J M J Vanderschure. Cannabis and the developing brain: insights from behavior. European journal of pharmacology. vol 585. issue 2-3. 2008-07-18. PMID:18413273. |
since cannabis preparations are widely used and abused by young people, including pregnant women, understanding how cannabinoid compounds affect the developing brain, leading to neurobehavioral alterations or neuropsychiatric disorders later in life, is a serious health issue. |
2008-07-18 |
2023-08-12 |
human |
| T Bisogn. Endogenous cannabinoids: structure and metabolism. Journal of neuroendocrinology. vol 20 Suppl 1. 2008-07-18. PMID:18426492. |
the finding of specific binding sites for delta(9)-tetrahydrocannabinol, the psychoactive component of cannabis sativa, has led to the discovery of the endocannabinoid system and has emphasised the physiological and pathological relevance of endocannabidoid lipid signalling. |
2008-07-18 |
2023-08-12 |
Not clear |